Already having an existing collab in diabetes, Eli Lilly and Germany’s Boehringer Ingelheim have today announced a new research pact, this time focused on…

MyoKardia is working on making good on its IPO last fall. It’s up by more than one-third on early data for its lead candidate in hypertrophic cardiomyopathy.

AstraZeneca has released $62 million for a license payment to partner FibroGen ($FGEN) as its experimental pill roxadustat continues its late-stage testing for…

Ablynx has posted rheumatoid arthritis data showing vobarilizumab can compete with Roche’s Actemra, but doubts remain about whether AbbVie will buy the drug.

Vertex and Moderna have partnered in a deal potentially worth more than $300 million to discover and develop messenger RNA therapeutics for cystic fibrosis.

Pfizer and research partner Merck KGaA have begun late-stage testing of their experimental checkpoint inhibitor avelumab with chemo in certain ovarian cancer…

Less than a week after stumping up cash for a one-drug-wonder biotech (and an option to buy it out), Japan’s Takeda has struck another biotech deal, this time…

Bristol-Myers Squibb and PsiOxus Therapeutics have partnered to put a pair of candidates into Phase I testing to treat several tumor types in late-stage cancer…